This week, we are tracking a software name with nine upward revisions in 60 days, an oil producer heading into a May report with a split earnings signal, and a gas producer where the valuation gap against cash flow has become harder to ignore.

If you want to get ahead of where the earnings story is pointing rather than where the price has been, stay with this one.

Energy

EQT Corp (NYSE: EQT) is back in the conversation because the valuation math is starting to look increasingly difficult to ignore. The stock is down about 12% over the past month, even after a 4.3% bounce in the last week, and at roughly $59, it is trading near 11.3x earnings.

That is well below a peer group that is priced closer to 22x. On a cash flow basis, the disconnect sharpens further, with free cash flow sitting around $3.3 billion and some frameworks pointing to intrinsic value closer to $155 per share.

The disconnect between what the business generates and what the stock reflects is the story right now.

Free Cash Flow of $3.3 Billion Is Not Reflected in the Current Multiple

At 11.3x earnings and a valuation that looks compressed against most DCF frameworks, the market is not giving EQT credit for its cash generation. If that $3.3 billion in free cash flow holds, the multiple looks increasingly difficult to justify on the downside.

LNG Demand Tailwinds Remain Intact Despite Soft Sentiment

The US natural gas structural story — LNG exports, energy security, long-term demand visibility — has not changed. Sentiment tends to move faster than fundamentals in energy, which is exactly what creates the kind of valuation reset you are watching here.

Technology

DocuSign (NASDAQ: DOCU) is showing up again, and the reason is not nostalgia for pandemic-era demand. We have nine upward earnings revisions in 60 days. That kind of consistent estimate movement tends to lead price, and the consensus has now settled around $4.43 per share for the current year. 

What makes the setup more interesting is the execution track record underneath the estimated moves. The company has averaged a 9.2% positive earnings surprise, which tells you expectations have been running conservative relative to actual delivery.

That pattern does not typically produce nine upward revisions randomly.

Nine Revisions in 60 Days Signal a Clear Shift in Market Expectations

That is a directional signal. When estimates move higher consistently across a 60-day window, valuation frameworks tend to follow. This is especially the case  in software, where the earnings multiple is closely tied to forward growth perception.

15% Growth Rate Holds Firm After the Earlier Valuation Reset

A 15.4% earnings growth rate keeps DocuSign firmly in the growth category even after the cooldown from earlier highs. 

Growth at this pace without extreme multiple expansion is a more durable setup than one where the story depends on multiple re-rating alone.

Energy

Chord Energy (NASDAQ: CHRD) heads into its May 5 earnings print with a headline that looks soft and a revision trend that says something different. Projected EPS sits at about $3.38 per share — down roughly 16% year over year — and revenue is expected to be near $1.08 billion, down around 11%. On the surface, this looks like a weak setup heading into results.

What complicates that read is what estimates have done over the past month. The company has beaten estimates in three of the last four quarters, including a recent positive 9% surprise, so the base case has not always captured actual performance.

Near-Term Estimates Revised Up 30% Even as Annual Comparisons Stay Negative

A 30% upward move in near-term estimates over one month reflects changing assumptions around pricing, costs, or production volumes right before results land. That kind of revision momentum into a print with a soft headline is exactly where the gap between expectation and outcome tends to open up.

Three Beats in Four Quarters Keeps the Surprise Case Alive

A track record of beating in three of the last four quarters tells you the baseline model has not consistently captured what the company delivers. That history matters heading into a report where the headline trend looks weak, but the short-term revision signal is pointing higher.

Takeda Pharmaceutical (NYSE: TAK) trades with a price-to-book of 1.01 against the industry average of 1.52, a price-to-sales of 1.73 versus the sector’s 3.43, and a price-to-cash-flow of 7.85 compared to 13.61 for peers.

Three separate valuation metrics all sitting well below the sector average at the same time is not a coincidence. It is a consistent discount on a stable global pharma cash engine. 

This week’s setup is about positioning in a name where value screens keep flagging it while the underlying business keeps generating cash. The risk is that pipeline setbacks or currency headwinds weigh on the forward earnings profile before the discount closes.

USANA Health Sciences (NYSE: USNA) is showing up across valuation screens with a PEG ratio of 0.78 against the industry average of 2.08, a price-to-book of 1.04 versus 1.62 for the sector, and a price-to-cash-flow of 8.43 compared to 14.48 across peers.

You are looking at a setup where earnings growth is priced more cheaply than comparable health and nutrition names across three different lenses at once. 

That kind of multi-metric discount tends to matter most when sentiment is neutral rather than overheated, which is exactly the current environment. The risk is that slowing direct sales volumes or international headwinds compress the earnings growth rate that the PEG ratio depends on to make the case.

Broadwind (NASDAQ: BWEN) has jumped roughly 31% over the past month while the broader market has been relatively steady, which puts the recent move in sharp contrast to its peer group.

Heading into earnings, the company is projecting a small per-share loss of about $0.07 alongside revenue near $33 million, which reflects ongoing top-line pressure. 

The price action ahead of that print suggests positioning is shifting before the report rather than after it, which tends to mean the setup has more going on beneath the surface than the headline forecasts imply.

The risk is that the earnings miss on both lines without any forward improvement disappoints the buyers who moved in early.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any [blank] stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge